No need for guidelines on conducting pharmacoeconomic analyses Newsletter Article 17 February 2013 Pages: 2 - 2
Influenza vaccination warrants a greater share of healthcare resources Richard Milne Newsletter Article 17 February 2013 Pages: 3 - 5
Cautious use of economic assessments needed to allocate healthcare resources Newsletter Article 17 February 2013 Pages: 6 - 7
Diagnosis poor predictor of use and cost of mental health services Newsletter Article 17 February 2013 Pages: 7 - 7
Substantial savings gained with anti-infective switch programme Newsletter Article 17 February 2013 Pages: 8 - 8
Surgery vs antineoplastic therapy for treating testicular cancer Newsletter Article 17 February 2013 Pages: 8 - 8
Pharmacists are key monitors of inappropriate prescribing Newsletter Article 17 February 2013 Pages: 9 - 9
Early switch from IV to oral cephalosporins is cost saving Newsletter Article 17 February 2013 Pages: 10 - 11
Switching from IV ceftriaxone to oral cefpodixime proxetil Newsletter Article 17 February 2013 Pages: 11 - 11
‘Willingness-to-pay’ approach useful for healthcare decision-making? Newsletter Article 17 February 2013 Pages: 13 - 13
GI disease management programme - cost savings predicted Newsletter Article 17 February 2013 Pages: 15 - 15
Comparing US FDA and industry pharmacoeconomic guidelines Newsletter Article 17 February 2013 Pages: 16 - 16